After years of effort to harness the immune system for the treatment of cancer, the advent of antibodies which target ‘immune checkpoints’, including programmed cell death protein 1 (PD-1) and cytotoxic lymphocyte antigen 4 (CTLA-4), has increased interest in immunological aspects of conventional therapies. This evidence concerns the gene CTLA4 and cancer.